冠心病患者血清糖基化终产物水平升高的意义  

Significance of serum advanced glycosylation end products in patients with coronary heart disease

作　　者：刘乃丰[1] 孙子林[1] 童嘉毅[1] 王伯荣[1] 徐标[1] 

机构地区：[1]南京铁道医学院附属医院心内科,210009

出　　处：《中华心血管病杂志》2001年第2期94-96,共3页Chinese Journal of Cardiology

基　　金：国家自然科学基金资助(39470314)

摘　　要：目的　探讨糖基化终产物 (AGEs)与冠心病的关系。方法　分别运用荧光法和ELISA法测定冠心病患者血清F AGE和E AGE水平 ,并与健康人、糖尿病患者比较。结果　 35例冠心病患者血清F AGE和E AGE水平分别为 (10 .4± 0 .6 )U/ml和 (14.7± 1.8)U/ml,明显高于健康人 [分别为(7.5± 0 .2 )U/ml,P <0 .0 1和 (8.6± 1.5 )U/ml,P <0 .0 0 0 1];但与糖尿病患者差异无显著性 [分别为(11.0± 0 .3)U/ml,P >0 .0 5和 (18.1± 1.3)U/ml,P >0 .0 5 ) ]。结论　增高的AGEs水平可能与冠心病发病有密切关系。Objective To investigate the relationship between advanced glycosylation end products (AGEs) and coronary heart disease(CHD). Methods Serum of 35 patients with CHD was collected for analyzing F AGE by fluorescence spectroscopy and E AGE by a competitive ELISA. Results The serum F AGE and E AGE of patients with CHD were significantly higher than those of control [(10.4±0.6) U/ml vs. (7.5±0.2) U/ml; P <0.01, and (14.7± 1.8) U/ml vs. (8.6±1.5) U/ml, P <0.000?1, respectively],but there were no significant differences between patients with CHD and those with diabetes mellitus [(10.4±0.6)] U/ml vs. (11.0±0.3) U/ml, P >0.05 and (14.7±1.8) U/ml vs. (18.1±1.3) U/ml, P >0.05, respectively). Conclusion Increased level of AGEs might be involved in the pathogenesis of CHD.

关 键 词：冠心病 血清 糖基化终产物 荧光法 ELISA法 

分 类 号：R541.4[医药卫生—心血管疾病]